These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16337372)

  • 1. A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG).
    Reed NS; Poole CJ; Coleman R; Parkin D; Graham JD; Kaye SB; Ostrowski J; Duncan I; Paul J; Hay A;
    Eur J Cancer; 2006 Jan; 42(2):179-85. PubMed ID: 16337372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
    Meden H; Wittkop Y; Kuhn W
    Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treosulfan as an effective second-line therapy in ovarian cancer.
    Gropp M; Meier W; Hepp H
    Gynecol Oncol; 1998 Oct; 71(1):94-8. PubMed ID: 9784326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
    Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
    Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
    Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
    Marsh S; Paul J; King CR; Gifford G; McLeod HL; Brown R
    J Clin Oncol; 2007 Oct; 25(29):4528-35. PubMed ID: 17925548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial.
    Chitapanarux I; Lorvidhaya V; Kamnerdsupaphon P; Sumitsawan Y; Tharavichitkul E; Sukthomya V; Ford J
    Eur J Cancer; 2007 Jun; 43(9):1399-406. PubMed ID: 17467265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
    Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
    Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.
    Dizon DS; Sabbatini PJ; Aghajanian C; Hensley ML; Spriggs DR
    Gynecol Oncol; 2002 Mar; 84(3):378-82. PubMed ID: 11855873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations.
    Belani CP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S10-22. PubMed ID: 19780242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
    J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.